Autoantibody-based Precision Immuno-Profiling and Therapeutics

In addition to producing antibodies against foreign molecules, the immune system generates antibodies to self-antigens (“autoantibodies”) in response to many pathological processes. Autoantibodies have several properties which make them excellent indicators of disease and their detection forms the basis of many in vitro diagnostic tests. It is believed that autoantibodies are generated through over-expression, mutation, release of proteins from damaged tissues, mis-folding or mis-presentation of proteins which leads to their recognition by the immune system.

Unlike other serological targets, autoantibodies are stable, highly specific, easily purified from serum, and are readily detectable with well-validated secondary reagents. Due to their inherent amplification within the immune system, autoantibodies are relatively abundant and are easily measured, making them ideal for early diagnosis of disease. The Sengenics Immunome protein array has been successfully used to identify predictive, pathologic and protective biomarkers for cancers, autoimmune and neurodegenerative diseases.

Order on Science Exchange

FEATURED PRODUCTS

High-throughput autoantibody profiling against 1600+ proteins

Quantification of autoantibodies to 200+ clinically relevant CT antigens

Simultaneous screening of 100+
wild-type and mutant p53

Multi-antigen, multi-domain
COVID-19 antibody test

Sengenics - Functional Proteomics | Krex Technology | Protein Microarray Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics UK Registered in England and Wales no. 12889389

X